home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

FDA Audit Checklist Clinical Trials Seminar 2018

 
  February 28, 2018  
     
 
NetZealous LLC DBA GlobalCompliancePanel, Courtyard Seattle Sea-Tac Area 16038 West Valley Highway Tukwila Washington 98188 USA
2018-04-26


Course "Managing Your FDA Inspection: Before, During and After" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.

 

Overview:

 

FDA's inspection program follows well-established procedures and conducts the inspections with as much consistency as possible. FDA trains its investigators from day one. During the first six months, they attend extensive classroom and hands on training. FDA investigators learn basic skills. As time goes on, special training is given and the field staff use detailed reference materials to guide their thinking, actions, decisions and conclusions. If you understand FDA's management of its investigators and inspectional process, you can keep your establishment ahead of a needless regulatory disaster. FDA conducts inspections with standard operating procedures and detailed information on how to handle almost any situation the FDA investigator may face. The course will let you see inside an FDA investigator's mind set and what the agency will do when it evaluates what the investigator says and documents. What the investigator does and what FDA does are not mysteries, they just seem like it.

 

Why you should attend:

 

"Hi, I'm from the FDA and here to conduct an inspection." What is the first thing you do? Ring a fire alarm, close down for the day (some firms have) or do you follow well-planned protocol. You think, "Why is FDA here? Are we in trouble?" Are you prepared to talk about the trouble you know you have with FDA regulations or is your plan of action to cross your fingers.

We all know that a bad FDA inspection has immediate and long-term consequences. The cost of fixing your problems, the bad public relations, upset customers and future business plans can be set into a downward spiral. If you do not understand what FDA is doing or thinking, how can you expect to deal successfully with FDA? If you don't know how to anticipate an investigator's actions or follow their train of thought, you will not be able to mitigate the effect of inspectional findings.

"Is FDA going to send us a Warning Letter?" You can make a reasonable prediction if you understand your inspectional results and how FDA will "grade" it. The tools are available.

 

Areas Covered in the Session

 

  • FDA legal authority
  • Types of inspections
  • FDA investigator training
  • FDA's written procedures, policy and operations guide
  • Industry inspection protocol
  • What to do and not do during an inspection
  • Form FDA 483 response
  • Warning Letter response
  • Enforcement

 

Who Will Benefit:

 

  • Regulatory Affairs
  • Quality Assurance
  • Manufacturing

 

Agenda:

 

Day 1 Schedule

 

Lecture 1:

FDA Inspection authority

  • FDA Inspection authority
  • Inspectional refusal prohibition

Lecture 2:

Types of Inspections: purpose, scope and scrutiny

  • Comprehensive GMP
  • Abbreviated GMP
  • District or Center Directed
  • Regulatory Follow-up
  • Surveillance
  • Limited
  • For Cause

Lecture 3:

Impact on you during and after inspection

  • How to interact with the FDA investigator
  • What not to say and do
  • Your protocol
  • Mismanagement of the inspection

Lecture 4:

FDA Investigator Training - This is what they are thinking

  • On the job training and supervision
  • Technical, classroom and mock inspections
  • Evidence development to tell the story
  • Physical and documentary samples of your violations
  • Writing reports, inspectional observations and sample documentation
  • Physical threats and assault

Lecture 5:

Investigations Operations Manual

  • Procedures and technical guidance. FDA's rules for themselves
  • FDA organization chart "in the field." Who is watching you?

Compliance Programs

  • Section III - the inspection / specific issues
  • Section V - the regulatory response / risk assessment

Lecture 6:

Investigations Operations Manual (continued)

  • Writing inspectional observations (Form FDA 483)
  • Writing establishment inspection reports
  • Evidence documentation and custody

Mock "Limited" inspection

Day 2 Schedule

 

Lecture 1:

FDA Form 483 - List of objectionable conditions, aka list of observations

  • Purpose
  • Format / organization
  • Managing 483 observations during the inspection
  • Responding to 483 observations during "discussion with management"
    • What it means
    • How to manage the discussion
    • How to challenge a 483 observation
    • What to say and not say

Lecture 2:

Your written response to a 483

  • Understanding the 483 - using an FDA issued 483
  • Time deadlines
  • Strategy for corrections and corrective action
  • Evidence of corrections and corrective action
  • Empty promises

Lecture 3:

FDA Warning Letter - advisory of possible legal action

  • FDA Warning Letter procedures
  • Responding to a Warning Letter - in 15 working days.

Group Hypothetical Warning Letter Response - in 10 minutes

Lecture 4:

FDA Enforcement Actions

  • Judicial
    • Seizure
    • Injunction
    • Prosecution
    • Monetary penalties
  • Administrative
    • Import / Export
    • Government contracts
    • Other government agency advisories
    • Fines
    • Premarket holds

 

Speaker

Casper Uldriks

ex-FDA Expert and former Associate Center Director of CDRH


Casper (Cap) Uldriks owns Encore Insight LLC, which provides consulting services on FDA Law. He brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and as an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. He is recognized as an exceptional and energetic speaker. His comments are candid, straightforward and of practical value. He understands how FDA thinks, operates and where it is headed.

 

Location:  Seattle, WA DateApril 26th & 27th, 2018 and Time: 9:00 AM to 6:00 PM

Venue:  Courtyard Seattle Sea-Tac Area   16038 West Valley Highway Tukwila Washington 98188 USA 

 

 

 

Price:

 

Register now and save $200. (Early Bird)

Price: $1,295.00 (Seminar Fee for One Delegate)

Until March 10, Early Bird Price: $1,295.00 From March 11 to April 24, Regular Price: $1,495.00

Register for 5 attendees   Price: $3,885.00      $6,475.00 You Save: $2,590.00 (40%)*

Register for 10 attendees   Price: $7,122.00   $12,950.00 You Save: $5,828.00 (45%)*

 

Sponsorship Program benefits for “Quality Assurance Auditing for FDA Regulated Industry” seminar

At this seminar, world-renowned FDA Regulated Industry subject matter experts interact with CXO’s of various designations. Executives who carry vast experience about FDA Regulated Industry and Experts get down to discussing industry-related best practices, regulatory updates, changes in technologies, and much more relating to FDA Regulated Industry.

As a sponsor of these seminars, you get the opportunity to have your product and company reach out to C-Level executives in FDA Regulatory -related industries and become known among these elite executives and subject matter experts. Apart from being seen prominently at these globally held seminars, you also get talked about frequently in our correspondences with our experts and these participants.

For More Information- https://www.globalcompliancepanel.com/control/sponsorship 

 

Contact us today!

 

NetZealous LLC DBA GlobalCompliancePanel

john.robinson@globalcompliancepanel.com  

support@globalcompliancepanel.com 

Toll free: +1-800-447-9407

Phone: +1-510-584-9661

 Website: http://www.globalcompliancepanel.com

 

Registration Link - https://www.globalcompliancepanel.com/control/globalseminars/~product_id=901411SEMINAR?SEO

Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel/

Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/

Follow us on Twitter: https://twitter.com/GCPanel

 
 
Organized by: GlobalCompliancePanel
Invited Speakers:

Casper Uldriks

ex-FDA Expert and former Associate Center Director of CDRH 

Casper (Cap) Uldriks owns Encore Insight LLC, which provides consulting services on FDA Law. He brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and as an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. He is recognized as an exceptional and energetic speaker. His comments are candid, straightforward and of practical value. He understands how FDA thinks, operates and where it is headed.

 
Deadline for Abstracts: 2018-04-24
 
Registration: https://www.globalcompliancepanel.com/control/globalseminars/~product_id=901411SEMINAR?april-2018-seo-hum-molgen
E-mail: support@globalcompliancepanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.